SUMMIT, N.J.--(BUSINESS WIRE)--
Celgene Corporation (NASDAQ:CELG) today announced the election of Julia
A. Haller, M.D., to its Board of Directors. Dr. Haller is
Ophthalmologist-in-Chief of the Wills Eye Hospital in Philadelphia, PA
where she holds the William Tasman, M.D. Endowed Chair. She serves as
Professor and Chair of the Department of Ophthalmology at Jefferson
Medical College of Thomas Jefferson University and Thomas Jefferson
University Hospitals, and is Co-Director of the Wills Vision Research
Center at Jefferson.
In 1986, Dr. Haller served as the first female Chief Resident at the
Wilmer Eye Institute at Johns Hopkins and later joined the Johns Hopkins
faculty. She was named the inaugural Katharine Graham Professor of
Ophthalmology in 2002, and the inaugural Robert Bond Welch, M.D.
Professor of Ophthalmology in 2006. In 2007, Dr. Haller assumed
leadership of Wills Eye Hospital.
Dr. Haller, one of the world's most renowned retina surgeons and
clinician-scientists, has received numerous academic and professional
honors and awards and has published over 300 scientific articles and
book chapters. Dr. Haller, who has been closely involved in the early
stage development of many new vision therapies and surgical procedures,
received her A.B. from Princeton University magna cum laude and
her M.D. from Harvard Medical School. She is a member of numerous
international scientific advisory boards and data and safety monitoring
committees, is a past member of the Board of Trustees of Princeton
University and has served as a consultant to Walter Reed Army Medical
Center and The Children's Hospital of Philadelphia.
"Julia is a world-renowned doctor and recognized leader in the medical
community, " said Bob Hugin, Chairman and CEO of Celgene Corporation.
"Her scientific expertise and significant experience in healthcare will
help guide the execution of our strategic vision."
Celgene Corporation, headquartered in Summit, New Jersey, is an
integrated global biopharmaceutical company engaged primarily in the
discovery, development and commercialization of innovative therapies for
the treatment of cancer and inflammatory diseases through gene and
protein regulation. For more information, please visit www.celgene.com.
Follow Celgene on Social Media: @Celgene,
This press release contains forward-looking statements, which are
generally statements that are not historical facts. Forward-looking
statements can be identified by the words "expects," "anticipates,"
"believes," "intends," "estimates," "plans," "will," "outlook" and
similar expressions. Forward-looking statements are based on
management's current plans, estimates, assumptions and projections, and
speak only as of the date they are made. We undertake no obligation to
update any forward-looking statement in light of new information or
future events, except as otherwise required by law. Forward-looking
statements involve inherent risks and uncertainties, most of which are
difficult to predict and are generally beyond our control. Actual
results or outcomes may differ materially from those implied by the
forward-looking statements as a result of the impact of a number of
factors, many of which are discussed in more detail in our Annual Report
on Form 10-K and our other reports filed with the Securities and
View source version on businesswire.com: http://www.businesswire.com/news/home/20151016005458/en/
Source: Celgene Corporation
News Provided by Acquire Media